Chaga Mushroom for Anti-Inflammatory

Research suggests that Chaga mushroom (Inonotus obliquus) possesses meaningful anti-inflammatory activity, with studies pointing to specific bioactive compounds — particularly the triterpenoid inotodiol, polysaccharides, and polyphenols — as likely contributors to this effect through mechanisms such as suppression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), inhibition of the enzyme iNOS, and modulation of signaling pathways including NF-κB and TLR3. The available evidence comes primarily from cell culture experiments and animal models, including studies on intestinal inflammation, skin inflammation, neuroinflammation, liver protection, and allergic immune responses, with two narrative reviews from 2023 and 2024 broadly affirming these findings across multiple biological systems. No randomized controlled trials in humans were identified among the reviewed literature, which represents a significant limitation, and one case report noted that excessive Chaga consumption was associated with oxalate-related kidney injury in a single patient, underscoring that high intake is not without risk. Studies indicate this is a promising area of investigation, but the evidence base remains largely preclinical, and conclusions about effectiveness or safety in humans cannot yet be drawn from the existing research.